Covishield, Covaxin Report

Brand Name

Monthly production of Covishield and Covaxin will be 120 and 58 million doses, respectively.

Latest updates of covid-19, get full details

Wednesday, 4th August 2021


The government today informed Rajya Sabha that the monthly production capacity of Covishield is expected to be increased to more than 120 million doses and that of Covaxin to around 58 million doses by December, citing information from COVID-19 vaccine manufacturers.

Union Health Minister Mansukh Mandaviya was responding to a question about the country's current capacity to manufacture Covaxin and Covishield, as well as the expected capacity from August to December 2021.

"As communicated by the manufacturers, Covishield's monthly vaccine production capacity is projected to be increased from 110 million doses per month to more than 120 million doses per month, and Covaxin's production capacity is projected to be increased from 25 million doses per month to around 58 million doses per month," the minister said in a written response.

Also read: Female Labor Participation Rate in India Plummets to 16.1% After Covid-19 Hurts the Economy.

 

Furthermore, the Ministry of Science and Technology's Department of Biotechnology has launched 'Mission Covid Suraksha - the Indian COVID-19 Vaccine Development Mission.'

According to the response, the Mission is being carried out by the Biotechnology Industry Research Assistance Council (BIRAC), a public sector undertaking (PSU) of the Department of Biotechnology.

Bharat Biotech, one state public sector enterprise, and two central public sector enterprises (PSEs) - Haffkine Biopharmaceutical Corporation Ltd, Mumbai; Indian Immunologicals Limited (IIL), Hyderabad; and Bharat Immunologicals Biologicals Limited (BIBCOL), Bulandshahr - have received support under the Mission for facility augmentation for Covaxin production.

Furthermore, technology transfer of Covaxin production to Gujarat COVID Vaccine Consortium (GCVC), which includes Hester Biosciences and OmniBRx Biotechnologies Pvt Ltd and is led by Gujarat Biotechnology Research Centre (GBRC) of the Department of Science and Technology, Government of Gujarat, has been facilitated, according to the response.

Furthermore, the Centre has provided financial assistance to one of the domestic manufacturers for 'At-risk manufacturing,' as well as advance payment against supply orders placed with Serum Institute of India and Bharat Biotech, as well as streamlining regulatory norms for vaccine approval, according to the response.

 

The News Talkie Bureau

Source

NDTV


Top Stories
Download video from a Converthub online ..
Impact Feature: अमेरिकन ..
South Newsmakers of Week: Ram Charan & S..
What Makes Gandhis CWC a Team Amidst the..
Kerala Sees a Dip in Total Covid-19 Case..
Bangladesh “Just not Good Enough”, S..
Udanpirappe Movie Review: A family drama..
5 Superfood-Enriched Products for Health..
5 Superfoods Against Anxiety and Stress..
5 Small Lifestyle Changes You Can Make t..